This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Dual Trigger Ovulation in Oocyte Donors (DUALTRIGGER)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2015 by Weill Medical College of Cornell University.
Recruitment status was:  Recruiting
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Weill Medical College of Cornell University Identifier:
First received: August 23, 2011
Last updated: June 10, 2015
Last verified: June 2015
The project is a randomized, controlled, prospective study of oocyte donors comparing the safety and efficacy of triggering ovulation using a combination of two drugs—GnRH agonist and very low dose hCG—versus triggering ovulation with a standard hCG dose alone or a standard GnRH trigger alone.

Condition Intervention Phase
Infertility Drug: HCG Drug: Lupron Trigger Drug: Dual Trigger Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Prospective Trial of Dual Trigger Ovulation in Oocyte Donors

Resource links provided by NLM:

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:
  • Number of Subjects Having Adverse Events [ Time Frame: 1 month ]
    Any donor having a serious complication such as severe hyperstimulation syndrome, ovarian torsion, infection or peritoneal bleeding will be recorded

  • Number of days post retrieval until subject is able to resume her usual activities [ Time Frame: 7 days post retrieval ]
    Subjects will complete a brief questionnaire on post retrieval day 7. They will state how many days after retrieval they were able to resume their usual activities.

  • Ovarian Volume [ Time Frame: 7 days post retrieval ]
    Ovarian volume of both ovaries will be measured by ultrasound on post op day number 7. Measurements will be taken in three different dimensions and volume calculated from those measurements.

Secondary Outcome Measures:
  • Number of mature oocytes retrieved [ Time Frame: 1 day post ovulation ]
    Number of mature oocytes retrieved will assess the efficacy of the intervention

  • Pregnancies per Transfer [ Time Frame: 4 weeks post retrieval ]
    Pregnancy rate per transfer will be assessed by hCG level on day 14 post retrieval and clinical pregnancy rate will be assessed by ultrasound on day 28 post retrieval. This will additionally assess efficacy of intervention.

Estimated Enrollment: 180
Study Start Date: January 2013
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: hCG
standard dose of hCG for ovulation trigger
Drug: HCG
hCG Trigger
Active Comparator: Lupron Trigger
Leuprolide acetate 2 mg ovulation trigger
Drug: Lupron Trigger
leuprolide acetate 2 mg SQ
Experimental: Dual Trigger
Lupron and hCG combined ovulation trigger
Drug: Dual Trigger
a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).

Detailed Description:

The study population will consist of young women, age 21 to 34, presenting to our facility with the desire to donate oocytes and who meet FDA and program requirements for donation.

Participants will be randomized to one of the three treatment interventions for triggering ovulation: 1) a standard dose of hCG, 2) leuprolide acetate 2 mg alone, or 3) a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).

Study participants who choose to repeat oocyte donation during the course of the study trial, and who consent to participate in the trial again, will be randomized in a cross-over manner for any subsequent trials.

Following randomization, the clinical care of study subjects will be the same as for non-participant oocyte donors. Participants in all three study arms will undergo standard ovarian stimulation protocol with gonadotropins, standard individualized adjustment of medication dose, standard criteria for administration of the ovulation trigger dose, and standard egg retrieval procedure.

The recipient population will be recruited from women, age 18 to 55, who present to our center wishing to become pregnant using donor oocytes. All prospective participants who meet the Center for Reproductive Medicine (CRM) criteria be recipients of donated eggs will be eligible to participate, should they wish to do so.

If a prospective recipient consents to participate in the study, then she would be matched with either a donor who is not participating in the study (and is receiving one of our standard triggers for ovulation) or a donor who is participating in the study and whose medication to trigger ovulation has been randomized into one of three groups: standard dose hCG, Leuprolide acetate, or a combination of low dose hCG and Leuprolide acetate.

A recipient who chooses to participate in the study will have no additional tests or procedures over the ones that she would normally do in order to receive donated eggs.


Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:


  • Young women, age 21 to 34, presenting to our facility with the desire to donate oocytes and meeting FDA and program requirements for donation.


  • Women, age 21 to 55, presenting to our facility with the desire to donate oocytes and meeting FDA and program requirements to be recipients of donated eggs.

Exclusion Criteria:


  • Less than 2 ovaries or any other significant ovarian abnormality
  • Does not meet current FDA or program requirements for donation.
  • A contraindication for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, clinically significant ovarian cysts)
  • A contraindication for the use of oral contraceptive pills (h/o thromboembolism, breast cancer, undiagnosed vaginal bleeding)
  • Known gene defects, genetic abnormalities or abnormal karyotype
  • Contraindication or hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol
  • Inability to give informed consent
  • Donors who, because of their place of residence or personal situation, would not be able to commit to all required time points including the one extra visit required by study participation.
  • The subject has a recent history of/or current epilepsy, thrombophilia, diabetes, cardiovascular, gastro-intestinal, hepatic, renal or pulmonary or auto-immune disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01443546

Contact: Ina Cholst, M.D. 646-962-2764
Contact: Rodriq Stubbs, N.P. 646-962-3276

United States, New York
Weill Cornell Medical College- Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine Recruiting
New York, New York, United States, 10021
Contact: Rodriq Stubbs, NP    646-962-3276   
Principal Investigator: Ina Cholst, M.D.         
Sponsors and Collaborators
Weill Medical College of Cornell University
Merck Sharp & Dohme Corp.
  More Information

Additional Information:
Responsible Party: Weill Medical College of Cornell University Identifier: NCT01443546     History of Changes
Other Study ID Numbers: 1011011394
Study First Received: August 23, 2011
Last Updated: June 10, 2015

Keywords provided by Weill Medical College of Cornell University:
oocyte donor
oocyte recipient
ovulation trigger

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents processed this record on June 23, 2017